Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Immunotherapy of Cancer Conference (ITOC) is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

ITOC 2022

The 9th Immunotherapy of Cancer Conference
22–24 September 2022 | Munich, Germany

ITOC 2022

The 9th Immunotherapy of Cancer Conference
22–24 September 2022 | Munich, Germany
The Immunotherapy of Cancer Conference (ITOC) is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.
Potentiating immunotherapy for bladder cancer via porphyrin-based PLZ4-nanoparticles 1:50
Potentiating immunotherapy for bladder cancer via porphyrin-based PLZ4-nanoparticles
Chong Xian Pan • 27 Sep 2022
Immunotherapy + chemotherapy for bladder cancer 0:28
Immunotherapy + chemotherapy for bladder cancer
Chong Xian Pan • 27 Sep 2022
The selection of PD-L1 escape variants in microsatellite stable metastatic CRC on avelumab treatment 3:59
The selection of PD-L1 escape variants in microsatellite stable metastatic CRC on avelumab treatment
Mascha Binder • 19 Sep 2022
CAR-T cells expressing a scFV targeting the hTSHR in thyroid cancer 2:39
CAR-T cells expressing a scFV targeting the hTSHR in thyroid cancer
Mascha Binder • 19 Sep 2022
The major hurdles of CAR-T cell therapy for solid tumors 0:41
The major hurdles of CAR-T cell therapy for solid tumors
Florian Märkl • 3 Oct 2022
Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanoma 2:11
Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanoma
Florian Märkl • 3 Oct 2022
The use of chemokines in cancer immunotherapy 1:58
The use of chemokines in cancer immunotherapy
Florian Märkl • 3 Oct 2022
ITOC 2022 highlights: B-cell engineering for cancer treatment 0:33
ITOC 2022 highlights: B-cell engineering for cancer treatment
Florian Märkl • 3 Oct 2022
Promoting the functional persistence of CAR-T cells in solid tumors via immune checkpoint blockade 2:01
Promoting the functional persistence of CAR-T cells in solid tumors via immune checkpoint blockade
Prasad Adusumilli • 27 Sep 2022
Armoring anti-HER2 CAR-T cells with CCR8 and a DNR to enable efficacy in solid tumor models 4:37
Armoring anti-HER2 CAR-T cells with CCR8 and a DNR to enable efficacy in solid tumor models
Thaddäus Strzalkowski • 29 Sep 2022
Challenges associated with CAR-T cells in solid tumors 1:28
Challenges associated with CAR-T cells in solid tumors
Thaddäus Strzalkowski • 29 Sep 2022
The synergistic antitumor activity of pan-PI3K inhibition and ICI’s in bladder cancer 1:36
The synergistic antitumor activity of pan-PI3K inhibition and ICI’s in bladder cancer
Chong Xian Pan • 29 Sep 2022
Addressing the unmet needs of immunotherapy in bladder cancer 0:54
Addressing the unmet needs of immunotherapy in bladder cancer
Chong Xian Pan • 29 Sep 2022
Overcoming the challenges faced with cellular therapies in solid tumors 3:10
Overcoming the challenges faced with cellular therapies in solid tumors
Sebastian Kobold • 27 Sep 2022
P329G-targeting CAR-T cells designed to target solid tumors 2:57
P329G-targeting CAR-T cells designed to target solid tumors
Sebastian Kobold • 27 Sep 2022
The use of RNA vaccines to promote CAR-T stimulation in solid tumors 2:02
The use of RNA vaccines to promote CAR-T stimulation in solid tumors
Sebastian Kobold • 27 Sep 2022

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals